- Home
- ZLAB vs ZYME Comparison
ZLAB vs ZYME Comparison
Compare ZLAB & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZLAB | ZYME |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2017 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ZLAB | ZYME |
|---|---|---|
| Price | $19.20 | $23.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $51.52 | $32.75 |
| AVG Volume (30 Days) | ★ 600.7K | 484.1K |
| Earning Date | 05-29-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.46 | 5.81 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $460,156,000.00 | $76,304,000.00 |
| Revenue This Year | $19.06 | $63.10 |
| Revenue Next Year | $18.58 | $93.26 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.33 | 0.38 |
| 52 Week Low | $15.96 | $9.03 |
| 52 Week High | $44.34 | $28.49 |
Technical Indicators
Market Signals| Indicator | ZLAB | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 52.53 | 49.13 |
| Support Level | $17.00 | $22.22 |
| Resistance Level | $19.70 | $23.66 |
| Average True Range (ATR) | 0.72 | 0.84 |
| MACD | 0.04 | 0.15 |
| Stochastic Oscillator | 59.77 | 45.85 |
Price Performance
Historical ComparisonAbout ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.